Vectura is a leader in the development of inhaled pharmaceuticals, using ideas, technologies and skills to create products to treat respiratory, neurological and other diseases – rapidly and effectively. Our goal is to improve patients’ lives and generate value for our stakeholders.
Press releases
15 April 2008Vectura announces positive data with inhaled anti-migraine product
2 April 2008Date of announcement of Preliminary Results for year ending 31 March 2008
17 January 2008Vectura Group Plc: Interim Management Statement 3 Months Ended 31 December 2007
Latest press releases Share price
| 56.50 GBp -5.50 | VEC.L | |
| Market cap GB£ | 195 | |
| Date | 16/05/2008 | |
Share price information Next events
22 May 2008Prelim Results for Year Ending 31 March 2008
28 May 2008
UBS Global Specialty and Generic Pharma Conference, London
Investor Calendar 
